Human Molecular Genetics, 2001, Vol. 10, No. 15 1563-1569
© 2001 Oxford University Press
Processing of ß-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex
Department of Neurology and Neuroscience, Teikyo University School of Medicine, Tokyo 173-8605, Japan, 1Banyu Tsukuba Research Institute, Tsukuba, Ibaraki 300-2611, Japan and 2Shionogi Research Laboratories, Shionogi & Co. Ltd, Osaka 553-0002, Japan
The dystroglycan complex is a membrane-spanning complex composed of two subunits,
- and ß-dystroglycan.
-dystroglycan is a cell surface peripheral membrane protein which binds to the extracellular matrix (ECM), whereas ß-dystroglycan is an integral membrane protein which anchors
-dystroglycan to the cell membrane. The dystroglycan complex provides a tight link between the ECM and cell membrane. Dysfunction of the dystroglycan complex has commonly been implicated in the molecular pathogenesis of severe forms of hereditary neuromuscular diseases, including Duchenne muscular dystrophy, Fukuyama-type congenital muscular dystrophy and sarcoglycanopathy (LGMD2C, -D, -E and -F). To begin to clarify the pathway by which the dysfunction of the dystroglycan complex could lead to muscle cell degeneration, we investigated the proteolytic processing of the dystroglycan complex in this study. We demonstrate that (i) a 30 kDa fragment of ß-dystroglycan is expressed in peripheral nerve, kidney, lung and smooth muscle, but not skeletal muscle, cardiac muscle or brain, and (ii) this fragment is the product of proteolytic processing of the extracellular domain of ß-dystroglycan by the membrane-associated matrix metalloproteinase (MMP) activity. Importantly, furthermore, we demonstrate that this processing disintegrates the dystroglycan complex. Our results indicate that the processing of ß-dystroglycan by MMP causes the disruption of the link between the ECM and cell membrane via the dystroglycan complex, which could have profound effects on cell viability. Based on these and previously reported findings, we propose a hypothesis that this processing may play a crucial role in the molecular pathogenesis of sarcoglycanopathy.
+ To whom correspondence should be addressed. Tel: +81 3 3964 1211; Fax: +81 3 3964 6394; Email: k-matsu@med.teikyo-u.ac.jp
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. J. Proszynski, J. Gingras, G. Valdez, K. Krzewski, and J. R. Sanes Podosomes are present in a postsynaptic apparatus and participate in its maturation PNAS, October 27, 2009; 106(43): 18373 - 18378. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Michaluk, L. Kolodziej, B. Mioduszewska, G. M. Wilczynski, J. Dzwonek, J. Jaworski, D. C. Gorecki, O. P. Ottersen, and L. Kaczmarek beta-Dystroglycan as a Target for MMP-9, in Response to Enhanced Neuronal Activity J. Biol. Chem., June 1, 2007; 282(22): 16036 - 16041. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Dean and C. M. Overall Proteomics Discovery of Metalloproteinase Substrates in the Cellular Context by iTRAQTM Labeling Reveals a Diverse MMP-2 Substrate Degradome Mol. Cell. Proteomics, April 1, 2007; 6(4): 611 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hnia, G. Hugon, F. Rivier, A. Masmoudi, J. Mercier, and D. Mornet Modulation of p38 Mitogen-Activated Protein Kinase Cascade and Metalloproteinase Activity in Diaphragm Muscle in Response to Free Radical Scavenger Administration in Dystrophin-Deficient Mdx Mice Am. J. Pathol., February 1, 2007; 170(2): 633 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohtake, H. Tojo, and M. Seiki Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle J. Cell Sci., September 15, 2006; 119(18): 3822 - 3832. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Agrawal, P. Anderson, M. Durbeej, N. van Rooijen, F. Ivars, G. Opdenakker, and L. M. Sorokin Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis J. Exp. Med., April 17, 2006; 203(4): 1007 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, I. A. Memon, N. Kawaguchi, N. Matsuura, and H. Matsuda Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 295 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Singh, Y. Itahana, S. Knight-Krajewski, M. Kanagawa, K. P. Campbell, M. J. Bissell, and J. Muschler Proteolytic Enzymes and Altered Glycosylation Modulate Dystroglycan Function in Carcinoma Cells Cancer Res., September 1, 2004; 64(17): 6152 - 6159. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, A. Davidovits, H. Poczewski, B. Langer, S. Uchida, K. Nagy-Bojarski, A. Hovorka, R. Sedivy, and D. Kerjaschki Podocyte Flattening and Disorder of Glomerular Basement Membrane Are Associated with Splitting of Dystroglycan-Matrix Interaction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2079 - 2089. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Brown, S. Torelli, M. Brockington, Y. Yuva, C. Jimenez, L. Feng, L. Anderson, I. Ugo, S. Kroger, K. Bushby, et al. Abnormalities in {alpha}-Dystroglycan Expression in MDC1C and LGMD2I Muscular Dystrophies Am. J. Pathol., February 1, 2004; 164(2): 727 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Boito, M Fanin, G Siciliano, C Angelini, and E Pegoraro Novel sarcoglycan gene mutations in a large cohort of Italian patients J. Med. Genet., May 1, 2003; 40(5): e67 - 67. [Full Text] [PDF] |
||||
![]() |
A. Sgambato, M. Migaldi, M. Montanari, A. Camerini, A. Brancaccio, G. Rossi, R. Cangiano, C. Losasso, G. Capelli, G. P. Trentini, et al. Dystroglycan Expression Is Frequently Reduced in Human Breast and Colon Cancers and Is Associated with Tumor Progression Am. J. Pathol., March 1, 2003; 162(3): 849 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Muschler, D. Levy, R. Boudreau, M. Henry, K. Campbell, and M. J. Bissell A Role for Dystroglycan in Epithelial Polarization: Loss of Function in Breast Tumor Cells Cancer Res., December 1, 2002; 62(23): 7102 - 7109. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rattenholl, W. N. Pappano, M. Koch, D. R. Keene, K. E. Kadler, T. Sasaki, R. Timpl, R. E. Burgeson, D. S. Greenspan, and L. Bruckner-Tuderman Proteinases of the Bone Morphogenetic Protein-1 Family Convert Procollagen VII to Mature Anchoring Fibril Collagen J. Biol. Chem., July 12, 2002; 277(29): 26372 - 26378. [Abstract] [Full Text] [PDF] |
||||










